Amytrx Therapeutics
Nashville
About Amytrx Therapeutics
Amytrx Therapeutics is a biopharmaceutical company that advances the next generation of new anti-inflammatory peptide therapies for patients with chronic inflammatory diseases. The company's AMTX-100 is bioengineered using human protein sequences that modulate the immune system by a natural process. Amytrx Therapeutics was founded in 2014 by Matthew A. Gonda and is based in Nashville, Tennessee.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $29.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2022)
- Website: amytrx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amytrx-therapeutics-66147 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.